On July 4th, Futu News reported that the three major Hong Kong stock indexes opened high and fell back in the morning session. The Hang Seng Index and H shares rose to 0.9% at the beginning of the session, but turned down before the lunch break. They each rose slightly by 0.05% and 0.03% respectively. The Hang Seng Tech Index's gains narrowed to 0.48%, after a surge of 2.3% at the beginning of the day.
![](https://postimg.futunn.com/news-editor-imgs/20240704/public/1720065652885468554847.png)
As of the midday close, there were 684 gainers, 913 decliners and 1471 unchanged stocks on the Hong Kong stock market.
![](https://postimg.futunn.com/news-editor-imgs/20240704/public/172006566043829304564.png)
In terms of sectors, network technology stocks rose more than fell, with Ctrip up more than 3%, Meituan up more than 2%, Bilibili up nearly 2%, and Kuaishou down nearly 4%.
The golden industrial concept led the gains, with Lingbao Gold rising nearly 6%, Zijin Mining, SD Gold, and Chi Silver GP all up more than 3%, and Zhaojin Mining up nearly 3%.
New energy vehicle companies performed strongly, with NIO up nearly 6%, Xpeng and LI Auto both up about 4%, and BYD Company up more than 2%.
Apple suppliers showed mixed results, with AAC Tech up 5%, Cowell up nearly 3%, and Sunny Optical down nearly 3%.
Property management stocks fell back, with Songdu Services down nearly 19%, Greentown Management Holdings down more than 7%, and China Resources Mixc down nearly 4%.
In terms of individual stocks,$FIT HON TENG (06088.HK)$Up nearly 7%, the company is expected to benefit from the two major demand for iPhone and AI servers.
$AAC TECH (02018.HK)$Up another 5%, the AI phone drives hardware upgrades, and the company's microphone and cooling solution are expected to benefit.
$ZHIHU-W (02390.HK)$Up more than 11%, the company released a new AI product, 'Zhihu Direct Answer', and expanded into the AI search market.
$YAN PALACE (01497.HK)$Up nearly 9%, institutions said that the bird's nest industry is relatively scattered, and the company has significant competitive advantages.
$ALPHAMAB-B (09966.HK)$Down more than 6%, the company's overseas development is blocked, and the core product's overseas clinical trial has failed.
TOP20 turnover in half a day
![](https://postimg.futunn.com/news-editor-imgs/20240704/public/17200657344205388948376.png)
Editor/Feynman